186 related articles for article (PubMed ID: 1315868)
1. Phenylmorphans and analogues: opioid receptor subtype selectivity and effect of conformation on activity.
Froimowitz M; Pick CG; Pasternak GW
J Med Chem; 1992 May; 35(9):1521-5. PubMed ID: 1315868
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity studies of morphine fragments. I. 4-alkyl-4-(m-hydroxy-phenyl)-piperidines.
Loew GH; Lawson JA; Uyeno ET; Toll L; Frenking G; Polgar W; Ma LY; Camerman N; Camerman A
Mol Pharmacol; 1988 Sep; 34(3):363-76. PubMed ID: 2843751
[TBL] [Abstract][Full Text] [Related]
4. Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
Spetea M; Greiner E; Aceto MD; Harris LS; Coop A; Schmidhammer H
J Med Chem; 2005 Jul; 48(15):5052-5. PubMed ID: 16033285
[TBL] [Abstract][Full Text] [Related]
5. Probes for narcotic receptor-mediated phenomena. 20. Alteration of opioid receptor subtype selectivity of the 5-(3-hydroxyphenyl)morphans by application of the message-address concept: preparation of delta-opioid receptor ligands.
Bertha CM; Flippen-Anderson JL; Rothman RB; Porreca F; Davis P; Xu H; Becketts K; Cha XY; Rice KC
J Med Chem; 1995 Apr; 38(9):1523-37. PubMed ID: 7739011
[TBL] [Abstract][Full Text] [Related]
6. Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action.
Horan PJ; Wild KD; Kazmierski WM; Ferguson R; Hruby VJ; Weber SJ; Davis TP; Fang L; Knapp RJ; Yamamura HI
Eur J Pharmacol; 1993 Mar; 233(1):53-62. PubMed ID: 8386089
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
[TBL] [Abstract][Full Text] [Related]
8. Metopon and two unique derivatives: affinity and selectivity for the multiple opioid receptors.
McLaughlin JP; Nowak D; Sebastian A; Schultz AG; Archer S; Bidlack JM
Eur J Pharmacol; 1995 Dec; 294(1):201-6. PubMed ID: 8788432
[TBL] [Abstract][Full Text] [Related]
9. Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.
Hiebel AC; Lee YS; Bilsky E; Giuvelis D; Deschamps JR; Parrish DA; Aceto MD; May EL; Harris LS; Coop A; Dersch CM; Partilla JS; Rothman RB; Cheng K; Jacobson AE; Rice KC
J Med Chem; 2007 Aug; 50(16):3765-76. PubMed ID: 17625813
[TBL] [Abstract][Full Text] [Related]
10. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
11. Substituted 1-(aminomethyl)-2-(arylacetyl)-1,2,3,4-tetrahydroisoquinolines: a novel class of very potent antinociceptive agents with varying degrees of selectivity for kappa and mu opioid receptors.
Vecchietti V; Clarke GD; Colle R; Dondio G; Giardina G; Petrone G; Sbacchi M
J Med Chem; 1992 Aug; 35(16):2970-8. PubMed ID: 1323679
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
[TBL] [Abstract][Full Text] [Related]
13. N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.
Thomas JB; Zheng X; Mascarella SW; Rothman RB; Dersch CM; Partilla JS; Flippen-Anderson JL; George CF; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 1998 Oct; 41(21):4143-9. PubMed ID: 9767649
[TBL] [Abstract][Full Text] [Related]
14. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
Ward SJ; Takemori AE
J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
[TBL] [Abstract][Full Text] [Related]
15. Use of the mouse vas deferens to determine mu, delta, and kappa receptor affinities of opioid antagonists.
Cohen ML; Mendelsohn LG; Mitch CH; Zimmerman DM
Receptor; 1994; 4(1):43-53. PubMed ID: 8038706
[TBL] [Abstract][Full Text] [Related]
16. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties.
Mathews JL; Fulton BS; Negus SS; Neumeyer JL; Bidlack JM
Neurochem Res; 2008 Oct; 33(10):2142-50. PubMed ID: 18528756
[TBL] [Abstract][Full Text] [Related]
17. Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist.
Endoh T; Matsuura H; Tajima A; Izumimoto N; Tajima C; Suzuki T; Saitoh A; Suzuki T; Narita M; Tseng L; Nagase H
Life Sci; 1999; 65(16):1685-94. PubMed ID: 10573186
[TBL] [Abstract][Full Text] [Related]
18. Involvement of spinal kappa opioid receptors in the antagonistic effect of dynorphins on morphine antinociception.
Song ZH; Takemori AE
Life Sci; 1991; 48(15):1447-53. PubMed ID: 1672725
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.
Spetea M; Schüllner F; Moisa RC; Berzetei-Gurske IP; Schraml B; Dörfler C; Aceto MD; Harris LS; Coop A; Schmidhammer H
J Med Chem; 2004 Jun; 47(12):3242-7. PubMed ID: 15163203
[TBL] [Abstract][Full Text] [Related]
20. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
